This dashboard presents an overview of upcoming patent expirations across key pharmaceutical products, highlighting the timeline, therapeutic diversity, and company-wise concentration. The analysis reflects potential areas for generic entry, market competition, and innovation turnover in the coming years.
The data indicates moderate concentration, with several companies holding multiple patents set to expire across diverse dosage forms and administration routes.
These top five companies together account for nearly 70% of all expirations, suggesting that a handful of mid- to large-scale innovators dominate this patent cycle.
The 2032–2035 cluster marks a major phase for market shifts and competitive openings.
The dominance of oral formulations signals a continued focus on patient convenience and large-market drug formats.
Several brands exhibit multiple patent protections, indicating layered IP strategies for formulation, process, and delivery innovations.
The analysis highlights a maturing patent landscape with a clear mid-decade expiry concentration. Companies like Karyopharm and SpringWorks lead the list, positioning 2025–2035 as a key transition window for potential generic entry and portfolio diversification. The high share of oral dosage patents suggests that post-expiry competition may intensify in widely prescribed therapeutic areas.
Overall, Q4 data reflects a balanced mix of near-term and long-term expirations, offering both immediate and strategic opportunities for manufacturers, formulators, and licensing partners.